Shari Belafonte Partners With VIVUS to Encourage Adults to Speak With Their
Doctors About Losing Weight and Treatment Options Now Available
Actress/Model's Struggle with Being Overweight and Concerns about
Weight-Related Diabetes, High Cholesterol Led to Asking Her Primary
Care Physician for Help
MOUNTAIN VIEW, CA -- (Marketwired) -- 03/19/14 -- VIVUS, Inc.
(NASDAQ: VVUS) today announced that Shari Belafonte is teaming up
with the company to educate American adults about seeking medical
treatment for chronic weight management when diet and physical
activity alone have not been successful. Ms. Belafonte, an actress,
model, photographer, writer, singer and daughter of famed musician
and actor Harry Belafonte, knows that the impact of being overweight
is more than superficial.
In recent years, Belafonte struggled with being overweight, developed
high cholesterol, and was increasingly concerned about a family
history that included cardiovascular disease and diabetes. She worked
with her primary care physician and was able to achieve her weight
loss goal with an available prescription medication as part of a plan
including proper nutrition and physical activity.
"I thought about the people I love and knew that I wanted to do more
to improve my health," said Belafonte. "It is such a relief to have
found the support of a physician who helped me set - and achieve - a
realistic 10% weight loss goal. Reaching and maintaining this lower,
healthier weight has made a real difference for me."
A 10% weight loss goal is recommended by the National Institutes of
Health as a benchmark to help patients reduce the risk of developing
other medical conditions while making a meaningful difference in
health and well-being.
Belafonte plans to share new photographic work featuring patients
like herself who have successfully achieved and maintained meaningful
weight loss, improving their health and well-being. She is an
accomplished photographer and videographer, commissioned by
production companies and numerous periodicals. Belafonte has staged
photographic exhibitions in major cities across the U.S.
The treatment of obesity is being taken more seriously in the midst
of a public epidemic in which more than 110 million Americans are
obese or overweight with at least one weight-related comorbidity.
This past year, the American Medical Association House of Delegates
approved a resolution to declare obesity a disease, encouraging
physicians to use a range of medical interventions to treat it.
Additionally, the American Association of Clinical Endocrinologists
has incorporated obesity management and FDA-approved medications for
the treatment of chronic weight management -- along with lifestyle
modifications -- into its recommendations for the treatment of
patients with diabetes, high cholesterol and hypertension.
VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in
obesity and sexual health. For more information about the company,
please visit www.vivus.com.
Certain statements in this press release are forward-looking within
the meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by the use of forward-looking
words such as "anticipate", "believe", "forecast", "estimate",
"expect", "intend", "likely", "may", "plan", "potential", "predict",
"opportunity" and "should", among others. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. VIVUS does not
undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in the
VIVUS Form 10-K for the year ending December 31, 2013, and periodic
reports filed with the Securities and Exchange Commission.
Dana B. Shinbaum
& Investor Relations
The Trout Group
Press spacebar to pause and continue. Press esc to stop.